[
  {
    "ts": null,
    "headline": "S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet",
    "summary": "The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a key report revealed softening inflation.",
    "url": "https://finnhub.io/api/news?id=9f6bedc416bb0a099c6e8612f88ead7e882564ac8da38e0faa4a8ea8bb440613",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748639529,
      "headline": "S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet",
      "id": 134908640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a key report revealed softening inflation.",
      "url": "https://finnhub.io/api/news?id=9f6bedc416bb0a099c6e8612f88ead7e882564ac8da38e0faa4a8ea8bb440613"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron stock sinks over trial data for smoker's lungs drug",
    "summary": "Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co-developed with Sanofi (SNY, SAN.PA). Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to speak more on this. Regeneron has put up a bid to acquire genetic testing firm 23andMe (ME) after the company filed for bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=3bf82545481886cbc4e2f8117b73ab87c899717837549d65091859c744484507",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748636610,
      "headline": "Regeneron stock sinks over trial data for smoker's lungs drug",
      "id": 134908641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co-developed with Sanofi (SNY, SAN.PA). Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to speak more on this. Regeneron has put up a bid to acquire genetic testing firm 23andMe (ME) after the company filed for bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=3bf82545481886cbc4e2f8117b73ab87c899717837549d65091859c744484507"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Decliners",
    "summary": "Medicus Pharma's (MDCX) shares slumped nearly 34% amid heavy trading Friday after the company priced",
    "url": "https://finnhub.io/api/news?id=187343f1998b84867ac40b7f91c660e4856d2f10e1e7ba24e0c1abc9d31f6d93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748629701,
      "headline": "Top Midday Decliners",
      "id": 134908642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Medicus Pharma's (MDCX) shares slumped nearly 34% amid heavy trading Friday after the company priced",
      "url": "https://finnhub.io/api/news?id=187343f1998b84867ac40b7f91c660e4856d2f10e1e7ba24e0c1abc9d31f6d93"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Rise -- Healthcare Roundup",
    "summary": "Healthcare Stocks Rise -- Healthcare Roundup",
    "url": "https://finnhub.io/api/news?id=13a64129f0533e45c9a079763716f4e10b1b8a4a393abce760d544a6374c0978",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748625420,
      "headline": "Healthcare Stocks Rise -- Healthcare Roundup",
      "id": 134946697,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Rise -- Healthcare Roundup",
      "url": "https://finnhub.io/api/news?id=13a64129f0533e45c9a079763716f4e10b1b8a4a393abce760d544a6374c0978"
    }
  },
  {
    "ts": null,
    "headline": "Why Regeneron (REGN) Shares Are Falling Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD).",
    "url": "https://finnhub.io/api/news?id=76730a00b25c5952bd86b03019c8854e52bf8b739297a45d96ef585a2c7a5dcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748623573,
      "headline": "Why Regeneron (REGN) Shares Are Falling Today",
      "id": 134908643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD).",
      "url": "https://finnhub.io/api/news?id=76730a00b25c5952bd86b03019c8854e52bf8b739297a45d96ef585a2c7a5dcf"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Nvidia, Dell, Ulta, Gap, Marvell, American Eagle, and More",
    "summary": "These Stocks Are Moving the Most Today: Nvidia, Dell, Ulta, Gap, Marvell, American Eagle, and More",
    "url": "https://finnhub.io/api/news?id=fa89c22c3d6e82c264a4ac4db76cb52fd88454558065bf87628e77007c2a690f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748587500,
      "headline": "These Stocks Are Moving the Most Today: Nvidia, Dell, Ulta, Gap, Marvell, American Eagle, and More",
      "id": 134894736,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "These Stocks Are Moving the Most Today: Nvidia, Dell, Ulta, Gap, Marvell, American Eagle, and More",
      "url": "https://finnhub.io/api/news?id=fa89c22c3d6e82c264a4ac4db76cb52fd88454558065bf87628e77007c2a690f"
    }
  },
  {
    "ts": null,
    "headline": "Unity upgrade, UiPath earnings, Regeneron drug trial results",
    "summary": "Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including Unity Software's (U) upgrade to Buy from Jefferies analysts, UiPath (PATH) beating its earnings estimates, and Regeneron Pharmaceuticals (REGN) taking a stock hit on its mixed drug trial results for an experimental treatment to a condition referred to as smoker's lung. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=9ba380f04f662b1cdafe8f15cb9591e9a366ac67d3257293fff290174f549f88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748621272,
      "headline": "Unity upgrade, UiPath earnings, Regeneron drug trial results",
      "id": 134904789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including Unity Software's (U) upgrade to Buy from Jefferies analysts, UiPath (PATH) beating its earnings estimates, and Regeneron Pharmaceuticals (REGN) taking a stock hit on its mixed drug trial results for an experimental treatment to a condition referred to as smoker's lung. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=9ba380f04f662b1cdafe8f15cb9591e9a366ac67d3257293fff290174f549f88"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More",
    "summary": "U.S. equities were lower at midday on concerns about where the U.S.-China trade war is heading.",
    "url": "https://finnhub.io/api/news?id=09ef1c739714c3e96636bb4cb7c54bab533f774064bef43339d788f0fd4eda60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748620767,
      "headline": "Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More",
      "id": 134907233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "U.S. equities were lower at midday on concerns about where the U.S.-China trade war is heading.",
      "url": "https://finnhub.io/api/news?id=09ef1c739714c3e96636bb4cb7c54bab533f774064bef43339d788f0fd4eda60"
    }
  },
  {
    "ts": null,
    "headline": "RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results",
    "summary": "Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on May 29. The rating comes as Regeneron awaits the findings of a phase III study on the medication candidate itepekimab, which is intended to treat chronic obstructive pulmonary disease (COPD). Based on a thorough analysis of preclinical […]",
    "url": "https://finnhub.io/api/news?id=cf077ac8ddfb08819fb0488f4f4fc3f32e55b5d299c7d0fd6cc0bb4643d48fc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748618906,
      "headline": "RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results",
      "id": 134908646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on May 29. The rating comes as Regeneron awaits the findings of a phase III study on the medication candidate itepekimab, which is intended to treat chronic obstructive pulmonary disease (COPD). Based on a thorough analysis of preclinical […]",
      "url": "https://finnhub.io/api/news?id=cf077ac8ddfb08819fb0488f4f4fc3f32e55b5d299c7d0fd6cc0bb4643d48fc0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure",
    "summary": "Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure",
    "url": "https://finnhub.io/api/news?id=6417747e2a15e5439eb5559c542b01aff7fae0f485bcbf7c377b0b26fd2506c8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748618340,
      "headline": "Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure",
      "id": 134946699,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure",
      "url": "https://finnhub.io/api/news?id=6417747e2a15e5439eb5559c542b01aff7fae0f485bcbf7c377b0b26fd2506c8"
    }
  },
  {
    "ts": null,
    "headline": "COPD Drug Developed by Regeneron, Sanofi Fails Key Test",
    "summary": "A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.",
    "url": "https://finnhub.io/api/news?id=1239d06f6da9dbade8c430444a8f5de107a390e33d39d7f96f5ab8f5248eee12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748615511,
      "headline": "COPD Drug Developed by Regeneron, Sanofi Fails Key Test",
      "id": 134903896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=1239d06f6da9dbade8c430444a8f5de107a390e33d39d7f96f5ab8f5248eee12"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies",
    "summary": "Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.",
    "url": "https://finnhub.io/api/news?id=cd4a3a55b0dc959d5add11ef5db5b0490fa8d86eb3102c8f6f980c75010d1432",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748614740,
      "headline": "Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies",
      "id": 134908648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.",
      "url": "https://finnhub.io/api/news?id=cd4a3a55b0dc959d5add11ef5db5b0490fa8d86eb3102c8f6f980c75010d1432"
    }
  },
  {
    "ts": null,
    "headline": "Itepekimab Failure A Setback For Sanofi And Regeneron",
    "summary": "Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks will weather the storm.",
    "url": "https://finnhub.io/api/news?id=4c67c09db92585a09147347813caead7b76634848b96542e2d9a731c69bd6aee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748614233,
      "headline": "Itepekimab Failure A Setback For Sanofi And Regeneron",
      "id": 134906485,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1171924987/image_1171924987.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks will weather the storm.",
      "url": "https://finnhub.io/api/news?id=4c67c09db92585a09147347813caead7b76634848b96542e2d9a731c69bd6aee"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure",
    "summary": "Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.",
    "url": "https://finnhub.io/api/news?id=8b0776632fe9374d797e79584cf6713f762f52d97970966b4a9878232377bb1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748609995,
      "headline": "Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure",
      "id": 134897351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.",
      "url": "https://finnhub.io/api/news?id=8b0776632fe9374d797e79584cf6713f762f52d97970966b4a9878232377bb1f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Stock Plunges. Why a Drug Trial Missed the Mark.",
    "summary": "Regeneron declined 10% to $544 in early trading.  U.S.-listed shares of Sanofi were down 4.8%.  The partners had touted their drug candidate itepekimab as a possible treatment for chronic obstructive pulmonary disease, or COPD, a condition caused by damage to the lungs that makes breathing difficult.",
    "url": "https://finnhub.io/api/news?id=1f90128263bdd70129c841f29ef5267d7ad5a7df144ebb9bd58b14f61c1d7232",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748608320,
      "headline": "Regeneron Stock Plunges. Why a Drug Trial Missed the Mark.",
      "id": 134903898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron declined 10% to $544 in early trading.  U.S.-listed shares of Sanofi were down 4.8%.  The partners had touted their drug candidate itepekimab as a possible treatment for chronic obstructive pulmonary disease, or COPD, a condition caused by damage to the lungs that makes breathing difficult.",
      "url": "https://finnhub.io/api/news?id=1f90128263bdd70129c841f29ef5267d7ad5a7df144ebb9bd58b14f61c1d7232"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients. Phase 3 AERIFY-1 trial evaluating itepekimab in adults who were former smokers with inadequately controlled COPD met the primary endpoint of significantly reducing moderate or severe acute exacerbations by 27% compared to placebo at week 52, a clinically meaningful benefit. A second Phase 3 trial, AERI",
    "url": "https://finnhub.io/api/news?id=cd276079007639bf4a3dbc68644d81070cc8b5b61d1bc67c56012e118865922a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748608247,
      "headline": "Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data",
      "id": 134897353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients. Phase 3 AERIFY-1 trial evaluating itepekimab in adults who were former smokers with inadequately controlled COPD met the primary endpoint of significantly reducing moderate or severe acute exacerbations by 27% compared to placebo at week 52, a clinically meaningful benefit. A second Phase 3 trial, AERI",
      "url": "https://finnhub.io/api/news?id=cd276079007639bf4a3dbc68644d81070cc8b5b61d1bc67c56012e118865922a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron shares slide on mixed trial data for smoker's lung drug",
    "summary": "(Reuters) -Regeneron shares fell 9% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called \"smoker's lung\" failed a late-stage trial, although it succeeded in another.  Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD).  The disease has limited treatment options and the drug, itepekimab, was expected to target a broader patient population compared to Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition.",
    "url": "https://finnhub.io/api/news?id=4c2844412ad3b4d92edf8f099e4255a1d6764d39629be30c007e3f89da015d9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748601462,
      "headline": "Regeneron shares slide on mixed trial data for smoker's lung drug",
      "id": 134897355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Reuters) -Regeneron shares fell 9% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called \"smoker's lung\" failed a late-stage trial, although it succeeded in another.  Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD).  The disease has limited treatment options and the drug, itepekimab, was expected to target a broader patient population compared to Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition.",
      "url": "https://finnhub.io/api/news?id=4c2844412ad3b4d92edf8f099e4255a1d6764d39629be30c007e3f89da015d9c"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials",
    "summary": "Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug candidate’s late-stage trials.",
    "url": "https://finnhub.io/api/news?id=55ce0fcd049a609dbc0370db3fa458075bcea9fd9699c88f7a2b9f4ed4ca32a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748601240,
      "headline": "Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials",
      "id": 134897356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug candidate’s late-stage trials.",
      "url": "https://finnhub.io/api/news?id=55ce0fcd049a609dbc0370db3fa458075bcea9fd9699c88f7a2b9f4ed4ca32a9"
    }
  },
  {
    "ts": null,
    "headline": "Mixed COPD results for Regeneron, Sanofi drug cloud approval chances",
    "summary": "Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner companies.",
    "url": "https://finnhub.io/api/news?id=c87f3a0f1df6229ccbe272ff01a9fc38229ef2dcb530d149cf4fafa89bbbfe63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748600304,
      "headline": "Mixed COPD results for Regeneron, Sanofi drug cloud approval chances",
      "id": 134903903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner companies.",
      "url": "https://finnhub.io/api/news?id=c87f3a0f1df6229ccbe272ff01a9fc38229ef2dcb530d149cf4fafa89bbbfe63"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Investors Q1 2025 Commentary",
    "summary": "abrdn Healthcare Investors Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=08a995b94c9843618fb019a74515636093294d133726b11dc86cee43c76ca7fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748595900,
      "headline": "abrdn Healthcare Investors Q1 2025 Commentary",
      "id": 134895434,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=08a995b94c9843618fb019a74515636093294d133726b11dc86cee43c76ca7fd"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi, Regeneron shares nosedive after mixed Itepekimab results",
    "summary": "Investing.com -- Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic obstructive pulmonary disease (COPD) treatment, Itepekimab.",
    "url": "https://finnhub.io/api/news?id=e7161285f2f8671e9d29a3035240d8e3599acac292aca1ddece15a0980126afa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748593552,
      "headline": "Sanofi, Regeneron shares nosedive after mixed Itepekimab results",
      "id": 134897357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic obstructive pulmonary disease (COPD) treatment, Itepekimab.",
      "url": "https://finnhub.io/api/news?id=e7161285f2f8671e9d29a3035240d8e3599acac292aca1ddece15a0980126afa"
    }
  },
  {
    "ts": null,
    "headline": "Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials",
    "summary": "AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did not meet the primary endpoint despite a benefit seen earlier in the trial Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials Regeneron and Sanofi are assessing the data and wi",
    "url": "https://finnhub.io/api/news?id=1532713d7c28fdcf1b7cb9aa65abc46d6f960f9c5e5a2853d332d938dd0f65cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748581200,
      "headline": "Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials",
      "id": 134880920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did not meet the primary endpoint despite a benefit seen earlier in the trial Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials Regeneron and Sanofi are assessing the data and wi",
      "url": "https://finnhub.io/api/news?id=1532713d7c28fdcf1b7cb9aa65abc46d6f960f9c5e5a2853d332d938dd0f65cf"
    }
  },
  {
    "ts": null,
    "headline": "2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar",
    "summary": "Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.",
    "url": "https://finnhub.io/api/news?id=6436030f750702c67af924c00e3c7a7cd4a1d893deae7494512393022463f702",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748579983,
      "headline": "2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar",
      "id": 134899575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.",
      "url": "https://finnhub.io/api/news?id=6436030f750702c67af924c00e3c7a7cd4a1d893deae7494512393022463f702"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults",
    "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use of itepekimab in adults who were former smokers with inadequately controlled...",
    "url": "https://finnhub.io/api/news?id=8ae0b5201b65857f8e9385c47fa89a0d9dfc4370d88e28a516d8260c9de5c010",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748570725,
      "headline": "Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults",
      "id": 134886049,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use of itepekimab in adults who were former smokers with inadequately controlled...",
      "url": "https://finnhub.io/api/news?id=8ae0b5201b65857f8e9385c47fa89a0d9dfc4370d88e28a516d8260c9de5c010"
    }
  }
]